Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.65 USD | -5.53% | -0.05% | -15.85% |
05-10 | Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 | MT |
04-30 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer | CI |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
AKERO THERAPEUTICS, INC. | Bio Therapeutic Drugs | -5.53% | -0.05% | -15.85% | -57.59% | - | 1.36B |
Technical Rankings Surperformance
- Stock Market
- Equities
- AKRO Stock
- Charts Akero Therapeutics, Inc.
- Comparison Chart